TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05541484
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See above.
Study: NCT06619236
Drug: Rina-S
Normalized name: S-2
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06619236
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT06619236
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06619236
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05331183
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT06657547
Drug: Salmeterol inhalation and urine samples
Normalized name: salmeterol Inhalant Product
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
Study: NCT06663137
Drug: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NDV01 is administered intravesically using a catheter.
Study: NCT06663306
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
Study: NCT06663306
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
Study: NCT06663007
Drug: RC48
Normalized name: RC48
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
Study: NCT06663007
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
Study: NCT06669013
Drug: dinutuximab beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy + Immunotherapy (dinutuximab beta)
Study: NCT06367374
Drug: Sonrotoclax
Normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.
Study: NCT06367374
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.
Study: NCT06533384
Drug: 9 cycles of Camrelizumab as adjuvant therapy.
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 cycles of Camrelizumab as adjuvant therapy.
Study: NCT05031624
Drug: CDX-0159
Normalized name: Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide wi
DrugBank: Barzolvolimab (DB18934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of one of four dosages of CDX-0159
Study: NCT05886192
Drug: norepinephrine+vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine combined with vasopressin to maintain blood pressure
Study: NCT00002445
Drug: IM862
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06293898
Drug: BL-M07D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
Study: NCT01549847
Drug: L-carnitine and piracetam
DrugBank: Piracetam (DB09210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine/piracetam (990mg/810mg) PO BID
Study: NCT05429684
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
Study: NCT05429684
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patuzumab (420mg iv.drip, d1,q3w)
Study: NCT05429684
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
Study: NCT05429684
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyroltinib (400mg po qd)
Study: NCT05429684
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
Study: NCT05429684
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (4mg, po, qd)
Study: NCT05429684
Drug: CDK4/6 inhibitor
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125mg, po, qd)
Study: NCT05429684
Drug: AI
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5mg, qd).
Study: NCT05429684
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cindilimab (200mg, iv.drip, d1, q3w)
Study: NCT05876572
Drug: intradermal naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
Study: NCT05494398
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
Study: NCT05020483
Drug: FEIBA
Normalized name: Feiba
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
Study: NCT05489926
Drug: Pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib, 60mg PO BID
Study: NCT06432712
Drug: Dexamethasone 4mg
Normalized name: DEXAMETHASONE 4MG TAB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5ml of Dexamethasone 4mg/ml will be administered via periapical infiltration with a 23 gauge needle to the experimental group.
Study: NCT06480071
Drug: Oxymetazoline, 0.05% Nasal Spray
Normalized name: Oxymetazoline, 0.05% nasal spray
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sprays each nostril before the excercise test.
Study: NCT06510465
Drug: utidelone
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
Study: NCT06510465
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
Study: NCT06510465
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
Study: NCT06510465
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
Study: NCT04920448
Drug: N-Acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05595499
Drug: Fisetin
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06479629
Drug: Piracetam
Normalized name: Piracetam
DrugBank: Piracetam (DB09210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg oral tablet of Piracetam three times every day for 3 months
Study: NCT06679582
Drug: Luveltamab tazevibulin
Normalized name: Luveltamab tazevibulin
DrugBank: Luveltamab tazevibulin (DB17563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.~Other Names:~* STRO-002~* Luvelta
Study: NCT06678074
Drug: Atibuclimab (IC14), 20 mg/kg intravenously, once
DrugBank: Atibuclimab (DB06546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody against CD14
Study: NCT06677970
Drug: BP lowering drugs (nicardipine, labetalol, urapidil)
Normalized name: biguanide blood glucose lower drugs
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After successful reperfusion, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
Study: NCT05376202
Drug: Cetuximab-IRDye800CW
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
Study: NCT05534334
Drug: Solu-Cortef
Normalized name: Solu-Cortef
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A vial sol. used for intra-mascular injection
Study: NCT05140278
Drug: Argesun 60mg (1 step parenteral artesunate)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
Study: NCT05140278
Drug: Artesun 60mg (2-step parenteral artesunate)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
Study: NCT04770155
Drug: Sildenafil 100 mg
Normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
Study: NCT04770155
Drug: Bosentan 125 mg
Normalized name: bosentan 125 MG
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
Study: NCT04806581
Drug: Allogeneic Hepatocyte
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic hepatocyte with cell numbers L,M,H respectively.
Study: NCT04827537
Drug: 20-hydroxyecdysone Oral
Normalized name: 20-Hydroxyecdysone
DrugBank: 20-Hydroxyecdysone (DB16935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days
Study: NCT04827537
Drug: Metronidazole Oral
Normalized name: metronidazole Oral Gel
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg (one pill) x two times a day orally, 10 consecutive days
Study: NCT06488326
Drug: Mulberry leaf extract 6 mg capsule
Normalized name: mulberry pollen extract
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one capsule of the sample one time.
Study: NCT06488326
Drug: Mulberry leaf extract 12 mg capsule
Normalized name: mulberry pollen extract
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one capsule of the sample one time.
Study: NCT06488326
Drug: Mulberry leaf extract 18 mg capsule
Normalized name: mulberry pollen extract
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one capsule of the sample one time.
Study: NCT06671028
Drug: Ropivacaine and Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
Study: NCT06671028
Drug: Ropivacaine 0,5%
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Popliteal sciatic block using ropivacaine 0.5% 20 mL
Study: NCT06673134
Drug: biological agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
Study: NCT06672224
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given subcutaneously
Study: NCT05418621
Drug: Enamel Matrix Derivative application
Normalized name: Matrix
DrugBank: Matrix-M (DB16369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
Study: NCT06029816
Drug: Neratinib tablets
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib tablets
Study: NCT06060405
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
Study: NCT06060405
Drug: Oleclumab
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
Study: NCT05835726
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
Study: NCT06534697
Drug: Naropin, 0.2% Injectable Solution in Sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
Study: NCT06377098
Drug: Sildenafil 50 mg Oral Tablet
Normalized name: sildenafil 50 MG Oral Tablet
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
Study: NCT04391868
Drug: Viagra Tablet
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet on Day 1 of each period
Study: NCT04391868
Drug: Sildenafil Citrate ODF
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg ODF on Day 1 of each period
Study: NCT06094179
Drug: Monoclonal antibody BAT6026
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
Study: NCT06094179
Drug: sodium chloride injection
Normalized name: Sodium Chloride Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
Study: NCT06534697
Drug: Dextrose 10 % in Water
Normalized name: dextrose 10 % in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
Study: NCT05442411
Drug: Ropivacaine 0.75% Injectable Solution
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of scalp block vs conventional post operative parecoxib
Study: NCT06553781
Drug: Temozolomide、Fruquintinib、Cadonilimab
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years.
Study: NCT06024005
Drug: Oral Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
Study: NCT05634590
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT04770272
Drug: Atezolizumab 840 MG in 14 ML Injection
Normalized name: atezolizumab 840 MG in 14 ML Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 840 mg Day 1 for two weeks
Study: NCT04770272
Drug: Atezolizumab 1200 MG in 20 ML Injection
Normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg Day 1 every 3 weeks for 8 cycles
Study: NCT04770272
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
Study: NCT04770272
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m² IV weekly x 12 cycles
Study: NCT04770272
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m2, day 1 for 4 cycles (12 weeks)
Study: NCT05844527
Drug: MRG-001
Normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
Study: NCT05844527
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile saline will serve as placebo treatment.
Study: NCT06532461
Drug: Novorapid
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Randomized to either Novorapid or Humalog
Study: NCT06532461
Drug: Humalog
Normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomized to either Novorapid or Humalog
Study: NCT05096169
Drug: Clomiphene Citrate 25mg
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clomiphene citrate at a dose of 25mg daily
Study: NCT05096169
Drug: Clomiphene Citrate 50mg
Normalized name: CLOMIPHENE CITRATE 50MG TAB
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clomiphene citrate at a dose of 50mg every other day
Study: NCT04855877
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
Study: NCT06172257
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Normalized name: Dexamethasone Ophthalmic Suspension
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Study: NCT04906005
Drug: gadopiclenol
Normalized name: Gadopiclenol
DrugBank: Gadopiclenol (DB17084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
Study: NCT06143579
Drug: FOLFOX-HAIC+Lenvatinib+Envolizumab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW \< 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles.